Saturday, March 18, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Health Security

CISAC Presents: A New Paradigm for Engaging the War on Infectious Diseases

by Global Biodefense Staff
April 9, 2013

Virus ModelingThe Center for International Security and Cooperation (CISAC) will be hosting a Science Seminar this month entitled “A New Paradigm for Engaging the War on Infectious Diseases.” The featured speaker is Dr. Jon C. Mirsalis, Managing Director of the Biosciences Division and Executive Director of Preclinical Development at SRI International in Menlo Park, CA.

The event will be held April 29, 2013 at Stanford University and is open to the public. 

About the seminar: 

From the 1950s through the 1970s, the success of antibiotics and vaccines in controlling or eradicating infectious diseases worldwide resulted in decreased emphasis on development of ID therapeutics. The emergence in the past three decades of HIV, SARS, West Nile, avian flu, swine flu, Ebola, and the potential for bioterrorist attacks has reversed this trend and renewed interest in treatment and prophylaxis of infectious diseases. 

Because many diseases are prevalent primarily in developing nations, potential sales of bioterrorist pathogens are limited mainly to orders for government stockpiles (e.g., anthrax, smallpox, botulinum toxin), and the cost of anti-infective clinical trials is high, traditional large pharmaceutical companies have cut back R&D resources in this arena.

To combat this investment shortfall, a new paradigm has emerged where public-private partnerships between the NIH, World Health Organization, private foundations, academia, and non-profits, are beginning to function like pharmaceutical companies to advance the development of promising infectious disease drugs, even when there is little opportunity for profit. This talk will discuss the growing need for infectious disease therapeutics, present some new models for discovering and developing them, and provide examples of public-private partnerships that have advanced therapeutics for specific infectious diseases.

About the speaker:

Dr. Mirsalis is an internationally recognized expert in the development of drugs for infectious diseases. He manages two large programs for the National Institute of Allergy and Infectious Diseases (NIAID) for the development of promising therapeutics for the prevention and treatment of a broad range of infectious diseases including TB, malaria, influenza, polio, anthrax, plague, and Ebola.

Before joining SRI in 1981, Dr. Mirsalis was a postdoctoral fellow at the Chemical Industry Institute of Toxicology, where he developed the in vivo-in vitro hepatocyte DNA repair assay, which is now widely used as a screen for potential carcinogens by government and industry.

Further details are available at the CISAC website. Please visit the Global Biodefense Calendar to view additional events.

Tags: AntimicrobialsAvian InfluenzaBotulinum NeurotoxinEbolaEmerging ThreatsEventsInfluenzaWest Nile

Related Posts

New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
Paxlovid Has Been Free So Far. Next Year, Sticker Shock Awaits.
Health Security

Paxlovid Has Been Free So Far. Next Year, Sticker Shock Awaits.

December 7, 2022
BARDA and JPEO-CBRND Back Cepheid’s Multiplex Test for Influenza, SARS-CoV2 and RSV
Health Security

Resurgent COVID-19, Flu and Other Viruses are Pushing New Zealand’s Health System to the Limit

June 2, 2022
Federal Select Agent Program Clarifies Requirements for Botulinum Neurotoxin Gene Constructs
Health Security

Federal Select Agent Program Clarifies Requirements for Botulinum Neurotoxin Gene Constructs

May 4, 2022
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC